

## Independent Medical Education Grants

1<sup>st</sup> Jan 2020 – 31<sup>st</sup> Mar 2020

Sanofi US and its affiliate Genzyme Corporation are committed to supporting independent medical education activities in therapeutic areas in which the Company is involved, for healthcare professionals, patients, and consumers to improve patient care and health outcomes in therapeutic areas in which the Company is engaged. Sanofi US and Genzyme Corporation are part of the Sanofi Group, a global pharmaceutical company.

Recipient Name(s) <sup>1</sup>	Activity Title	Funding Amount <sup>2</sup>
Cedars Sinai Medical Center	Novel Approaches to Diagnosis and Treatment of Antibody Rejection 2020 Symposium	\$10,000
Medscape, LLC	Antiarrhythmic Drugs in AF: A Deep Dive Into Recent Real-World Data	\$289,575
Physicians' Education Resource, LLC (PER)	Stem Cell Mobilization 101: Maximizing Outcomes in Patients with Multiple Myeloma and Non-Hodgkin's Lymphoma	\$307,895
UT Southwestern Medical Center	42nd Annual Carrell Krusen Neuromuscular Symposium	\$10,000
Physicians' Education Resource, LLC (PER)	"D" is for Diagnosis: Solving the Mystery of Lysosomal Storage Disorders – Meeting Series Extension	\$99,928
National Kidney Foundation	Improving Renal Outcomes in Fabry Disease	\$247,410
EXCEL Continuing Education	Lysosomal Storage Disorders: Neurological Manifestations	\$58,600
Postgraduate Institute for Medicine CMEducation Resource, LLC	The iQ&A Case-by-Case, Atopic Dermatitis (AD) Medical Intelligence Zone: Focus on the Evidence, Guidelines, Rationale, Mechanisms and Trials Supporting Biologics-Based, Therapeutic Targeting of Type 2 Cytokine Signaling Proteins for Moderate-to-Severe AD in Adolescents, Children, and Adults	\$181,000 <sup>3</sup>
Haymarket Medical Education	A Deeper Look into Moderate to Severe Atopic Dermatitis	\$349,360 <sup>3</sup>
Continuing Education Alliance dba Practicing Clinicians Exchange (PCE)	The Continuum of Care in Atopic Dermatitis: Advances in Management	\$395,000 <sup>3</sup>
Consortium of Multiple Sclerosis Centers	Grasping Precision Medicine in Multiple Sclerosis: 2020 Education Series for Beginners, Mid-Level and Experienced Clinicians	\$50,000

<sup>1</sup> Applicant names are provided by the requestor. If applicants apply as a group for a single educational activity; all applicants may or may not be identified above. The Company funds other educational activities (including fellowships and non-physician and patient education); which are not included in this report.

<sup>2</sup> "Funding Amount" is the amount that the Company funded during Q1 2020 identified above based upon an agreement. Recipients are required to return any unused funds. Information on unused funds returned by the applicant on activities are not reported. "Funding Amount" does not include funds that may have been provided by other affiliated Sanofi Company Entities, (e.g., Sanofi Pasteur)

<sup>3</sup> Collaboration (Shared) Funding – is the full amount of a grant funded under an agreement with Regeneron, some or all of which may be shared between the collaborating entities.

## Independent Medical Education Grants

1<sup>st</sup> Jan 2020 – 31<sup>st</sup> Mar 2020

Sanofi US and its affiliate Genzyme Corporation are committed to supporting independent medical education activities in therapeutic areas in which the Company is involved, for healthcare professionals, patients, and consumers to improve patient care and health outcomes in therapeutic areas in which the Company is engaged. Sanofi US and Genzyme Corporation are part of the Sanofi Group, a global pharmaceutical company.

Recipient Name(s) <sup>1</sup>	Activity Title	Funding Amount <sup>2</sup>
Postgraduate Institute for Medicine Enquiring Minds, LLC	Adolescents with MS – Expert Guidance on Navigating Therapeutic, Behavioral and Cognitive Challenges	\$40,000
Med Learning Group Uma Mlg LLC	A 3D Experience: Selecting Disease-Modifying Therapy for Multiple Sclerosis: Tools to Achieve and Maintain Control of a Dynamic Disease	\$50,000
Johns Hopkins University School of Medicine Johns Hopkins University Office of Continuing Medical Education	The Johns Hopkins University School of Medicine eMultipleSclerosis Review Volume 3	\$60,000
Eastern Virginia Medical School	Multiple Sclerosis Symposium 2020	\$5,000
USF Health	Breakfast with the Investigators: Management of Prostate Cancer - An Independent Satellite Symposium	\$50,000
Physicians' Education Resource, LLC (PER)	24th Annual International Congress on Hematologic Malignancies <sup>®</sup> : Focus on Leukemias, Lymphomas and Myeloma	\$50,000
National Association of Managed Care Physicians	New Horizons in the Treatment and Management of Relapsed/Refractory Multiple Myeloma: What Managed Care Needs to Know About Emerging Therapies	\$95,000
Physicians' Education Resource, LLC (PER)	Oncology Briefings <sup>™</sup> : Best Practices for the Prevention and Management of Tumor Lysis Syndrome	\$60,525
Physicians' Education Resource, LLC (PER)	New York GU <sup>™</sup> : 13th Annual Interdisciplinary Prostate Cancer Congress <sup>®</sup> and other Genitourinary Malignancies	\$50,000
Physicians' Education Resource, LLC (PER)	Advances in Oncology Nursing: Recognizing and Treating Oncologic Emergencies in the Cancer Patient	\$75,000

<sup>1</sup> Applicant names are provided by the requestor. If applicants apply as a group for a single educational activity; all applicants may or may not be identified above. The Company funds other educational activities (including fellowships and non-physician and patient education); which are not included in this report.

<sup>2</sup> "Funding Amount" is the amount that the Company funded during Q1 2020 identified above based upon an agreement. Recipients are required to return any unused funds. Information on unused funds returned by the applicant on activities are not reported. "Funding Amount" does not include funds that may have been provided by other affiliated Sanofi Company Entities, (e.g., Sanofi Pasteur)

<sup>3</sup> Collaboration (Shared) Funding – is the full amount of a grant funded under an agreement with Regeneron, some or all of which may be shared between the collaborating entities.

## Independent Medical Education Grants

**1<sup>st</sup> Jan 2020 – 31<sup>st</sup> Mar 2020**

Sanofi US and its affiliate Genzyme Corporation are committed to supporting independent medical education activities in therapeutic areas in which the Company is involved, for healthcare professionals, patients, and consumers to improve patient care and health outcomes in therapeutic areas in which the Company is engaged. Sanofi US and Genzyme Corporation are part of the Sanofi Group, a global pharmaceutical company.

Recipient Name(s) <sup>1</sup>	Activity Title	Funding Amount <sup>2</sup>
USF Health	Oncology Grand Rounds: Prostate Cancer -- A Case-Based Independent Satellite Symposium	\$50,000
Projects In Knowledge	Ask the Experts: New Relapsed/Refractory Multiple Myeloma Therapies for Late-Line Treatment—the Eleventh-Hour Heroes	\$125,000
USF Health	Exploring Clinical Investigator Perspectives on the Optimal Management of Patients with Multiple Myeloma — An Enduring Multimedia CME Resource for General Medical and Hematologic Oncologists and Fellows	\$40,000
Pennsylvania State University Penn State College of Medicine	Practical Guidance on Managing Prostate Cancer: How Urologists Can Master the Complexities of Patient Care in an Era of Novel Therapeutics	\$30,000
Pennsylvania State University Penn State College of Medicine	How I Think, How I Treat - Understanding Innovation in Multiple Myeloma: New Models for Attacking Disease Across the Clinical Spectrum	\$75,000
Physicians' Education Resource, LLC (PER)	Advances In™ Hematology: Assessing the Role of Monoclonal Antibodies for the Treatment of Multiple Myeloma	\$40,000
UMA Education Inc dba Global Education Group	Emerging Strategies in Relapsed/Refractory Multiple Myeloma	\$61,500
USF Health i3 Health	Multiple Myeloma: Enhancing Treatment Tolerability, Adherence and Patient-Centered Care	\$65,590
Continuing Education Alliance Continuing Education Alliance dba Practicing Clinicians Exchange	New Treatment Paradigms in Relapsed/Refractory Multiple Myeloma: Integrating Novel Agents into Clinical Practice	\$50,000
EXCEL Continuing Education	Shifting the Paradigm in the Management of Hemophilia A: Transitioning to a Young Adult	\$84,336

<sup>1</sup> Applicant names are provided by the requestor. If applicants apply as a group for a single educational activity; all applicants may or may not be identified above. The Company funds other educational activities (including fellowships and non-physician and patient education); which are not included in this report.

<sup>2</sup> "Funding Amount" is the amount that the Company funded during Q1 2020 identified above based upon an agreement. Recipients are required to return any unused funds. Information on unused funds returned by the applicant on activities are not reported. "Funding Amount" does not include funds that may have been provided by other affiliated Sanofi Company Entities, (e.g., Sanofi Pasteur)

<sup>3</sup> Collaboration (Shared) Funding – is the full amount of a grant funded under an agreement with Regeneron, some or all of which may be shared between the collaborating entities.

## Independent Medical Education Grants

1<sup>st</sup> Jan 2020 – 31st Mar 2020

Sanofi US and its affiliate Genzyme Corporation are committed to supporting independent medical education activities in therapeutic areas in which the Company is involved, for healthcare professionals, patients, and consumers to improve patient care and health outcomes in therapeutic areas in which the Company is engaged. Sanofi US and Genzyme Corporation are part of the Sanofi Group, a global pharmaceutical company.

Recipient Name(s) <sup>1</sup>	Activity Title	Funding Amount <sup>2</sup>
Boston University School of Medicine Office of CME Rockpointe Corporation	Improving Rheumatoid Arthritis Care: Understanding the Latest Approvals and Treatment Strategies	\$87,500

<sup>1</sup> Applicant names are provided by the requestor. If applicants apply as a group for a single educational activity; all applicants may or may not be identified above. The Company funds other educational activities (including fellowships and non-physician and patient education); which are not included in this report.

<sup>2</sup> "Funding Amount" is the amount that the Company funded during Q1 2020 identified above based upon an agreement. Recipients are required to return any unused funds. Information on unused funds returned by the applicant on activities are not reported. "Funding Amount" does not include funds that may have been provided by other affiliated Sanofi Company Entities, (e.g., Sanofi Pasteur)

<sup>3</sup> Collaboration (Shared) Funding – is the full amount of a grant funded under an agreement with Regeneron, some or all of which may be shared between the collaborating entities.

## Independent Medical Education Grants

1<sup>st</sup> Apr 2020 – 30<sup>th</sup> Jun 2020

Sanofi US and its affiliate Genzyme Corporation are committed to supporting independent medical education activities in therapeutic areas in which the Company is involved, for healthcare professionals, patients, and consumers to improve patient care and health outcomes in therapeutic areas in which the Company is engaged. Sanofi US and Genzyme Corporation are part of the Sanofi Group, a global pharmaceutical company.

Recipient Name(s) <sup>1</sup>	Activity Title	Funding Amount <sup>2</sup>
UMA Education Inc dba Global Education Group	Cutting Edge of Transplantation: Transplant Summit 2020 – Balancing Equity and Utility in the Face of an Organ Shortage	\$40,000
Postgraduate Healthcare Education, LLC	The Patient’s Voice: A Pharmacist’s Role in Improving Quality of Life Outcomes in Patients with Renal Transplants	\$65,500
Med-IQ	It Takes Two to Tango : A Combined Patient/Provider Education Strategy to Examine the Evidence, Barriers, and Opportunities for Fixed Ratio Combinations of GLP-1 and Insulin	\$325,452
National Association of Managed Care Physicians	Treatment Advances for Challenging Patients with Type 2 Diabetes: What Managed Care Needs to Know About Fixed-Ratio Combinations of Basal Insulin and GLP-1 Receptor Agonists	\$105,420
The University of Chicago	5th International Workshop on the Biology, Prevention, and Treatment of Relapse after Hematopoietic Stem Cell Transplantation and Cellular Therapy	\$42,105
ScientiaCME	Advances in the Management of Fabry Disease	\$19,100
Physicians' Education Resource, LLC (PER)	"D" is for Diagnosis: Detecting and Treating Rare Disorders in Hematologic Practice	\$275,000
Postgraduate Institute for Medicine Enquiring Minds, LLC	Rare Diseases and the Non-Physician Provider: Expert Guidance on Recognizing and Managing Lysosomal Storage Disorders	\$94,025
Ciné-Med, Inc. Tufts Medical Center, Inc	International Summit VII 2020: Hypertrophic Cardiomyopathy – A Contemporary and Treatable Disease: Moving Toward a Cure	\$30,000
Gordon Research Conferences	Bioanalytical Sensors Gordon Research Seminar: Translational Applications of Sensor Technologies	\$1,000

<sup>1</sup> Applicant names are provided by the requestor. If applicants apply as a group for a single educational activity; all applicants may or may not be identified above. The Company funds other educational activities (including fellowships and non-physician and patient education); which are not included in this report.

<sup>2</sup> "Funding Amount" is the amount that the Company funded during Q2 2020 identified above based upon an agreement. Recipients are required to return any unused funds. Information on unused funds returned by the applicant on activities are not reported. "Funding Amount" does not include funds that may have been provided by other affiliated Sanofi Company Entities, (e.g., Sanofi Pasteur)

<sup>3</sup> Collaboration (Shared) Funding – is the full amount of a grant funded under an agreement with Regeneron, some or all of which may be shared between the collaborating entities.

## Independent Medical Education Grants

1<sup>st</sup> Apr 2020 – 30<sup>th</sup> Jun 2020

Sanofi US and its affiliate Genzyme Corporation are committed to supporting independent medical education activities in therapeutic areas in which the Company is involved, for healthcare professionals, patients, and consumers to improve patient care and health outcomes in therapeutic areas in which the Company is engaged. Sanofi US and Genzyme Corporation are part of the Sanofi Group, a global pharmaceutical company.

Recipient Name(s) <sup>1</sup>	Activity Title	Funding Amount <sup>2</sup>
ScientiaCME	Genetic Disorders: Updates from The 16th Annual World Symposium	\$17,900
Postgraduate Institute for Medicine P2P Syncro	Achieving a Timely Diagnosis of MPS with Innovative Programming and Metrics - MPS I, MPS II and MPS VII	\$32,086
American Academy of CME, Inc	MPS I – A Faster Diagnosis Leads to Better Outcomes	\$75,000
Physicians' Education Resource, LLC (PER)	Advances in™ Pompe Disease: Opportunities to Improve Prognosis through Early Detection and New Treatments	\$124,795
AKH, Inc Catalyst Medical Education, LLC.	Evaluating Strategies to Improve the Recognition and Management of Mucopolysaccharoidosis Type 1	\$150,000
PRIME Education, LLC	Activating Patients and Providers in Shared Treatment Decisions for Atopic Dermatitis	\$234,450 <sup>3</sup>
Med Learning Group	Improving the Ability to Diagnose and Treat Atopic Dermatitis in Clinical Practice	\$249,800 <sup>3</sup>
Integritas Communications	Clinical SnapShots of Moderate-to-Severe Atopic Dermatitis: Pathophysiology, Multimodal Management, and Shared Clinical Decision Making	\$180,270 <sup>3</sup>
WEBMD GLOBAL LLC	A Virtual Dermatology Clinic: Can You Help These Patients Control Their Atopic Dermatitis?	\$350,000 <sup>3</sup>
Ultimate Medical Academy, LLC dba: Global Education Group Pri-med Institute, LLC	Advancing the Quality of Care for Patients with Atopic Dermatitis	\$149,905 <sup>3</sup>
Medscape LLC	Management of Severe Asthma in 2020: An Immersive Virtual Simulation Program	\$253,675 <sup>3</sup>

<sup>1</sup> Applicant names are provided by the requestor. If applicants apply as a group for a single educational activity; all applicants may or may not be identified above. The Company funds other educational activities (including fellowships and non-physician and patient education); which are not included in this report.

<sup>2</sup> "Funding Amount" is the amount that the Company funded during Q2 2020 identified above based upon an agreement. Recipients are required to return any unused funds. Information on unused funds returned by the applicant on activities are not reported. "Funding Amount" does not include funds that may have been provided by other affiliated Sanofi Company Entities, (e.g., Sanofi Pasteur)

<sup>3</sup> Collaboration (Shared) Funding – is the full amount of a grant funded under an agreement with Regeneron, some or all of which may be shared between the collaborating entities.

## Independent Medical Education Grants

1<sup>st</sup> Apr 2020 – 30<sup>th</sup> Jun 2020

Sanofi US and its affiliate Genzyme Corporation are committed to supporting independent medical education activities in therapeutic areas in which the Company is involved, for healthcare professionals, patients, and consumers to improve patient care and health outcomes in therapeutic areas in which the Company is engaged. Sanofi US and Genzyme Corporation are part of the Sanofi Group, a global pharmaceutical company.

Recipient Name(s) <sup>1</sup>	Activity Title	Funding Amount <sup>2</sup>
Postgraduate Healthcare Education, LLC	Atopic Dermatitis: Curbing the Cascade of Symptoms in Pediatric Patients	\$60,500 <sup>3</sup>
Vindico Medical Education, LLC	Immunology Bootcamp: An Immersive Educational Workshop in Conjunction with the Florida Rheumatology Society Annual Meeting	\$50,000
Postgraduate Institute for Medicine	Severe Asthma Telementoring Bootcamp	\$292,000 <sup>3</sup>
National Association For Continuing Education	3rd Annual Conversations in Dermatology Advances in Moderate to Severe Atopic Dermatitis: Impacting the Inflammation	\$134,585 <sup>3</sup>
Alaska Regional Hospital Asthma & Allergy Foundation of America, Alaska Chapter	Wheezin', Sneezin' and Itchin' in Alaska	\$5,000 <sup>3</sup>
Postgraduate Healthcare Education, LLC	Utilization of Patient Reported Outcomes in Asthma Management: Moving Beyond Adherence Measures	\$181,015 <sup>3</sup>
Med-IQ, Inc.	Attacking the Mechanisms of Moderate to Severe Atopic Dermatitis with Targeted Biologics	\$215,840 <sup>3</sup>
Continuing Education Alliance	Optimizing Outcomes in Moderate to Severe Asthma: Utilizing Biologic Therapy for Individualized Treatment	\$395,000 <sup>3</sup>
Horizon CME, Inc.	Children and Adolescents with Moderate-to-Severe AD: Improving Outcomes with Targeted Therapies	\$252,850 <sup>3</sup>
Purdue University	Sniffing Out New Strategies to Improve Diagnosis and Management of Chronic Rhinosinusitis with Nasal Polyps	\$200,000 <sup>3</sup>
Med-IQ, Inc.	Deconstructing Difficult-to-Treat Asthma in the Age of Targeted Biologic Therapies	\$215,840 <sup>3</sup>

<sup>1</sup> Applicant names are provided by the requestor. If applicants apply as a group for a single educational activity; all applicants may or may not be identified above. The Company funds other educational activities (including fellowships and non-physician and patient education); which are not included in this report.

<sup>2</sup> "Funding Amount" is the amount that the Company funded during Q2 2020 identified above based upon an agreement. Recipients are required to return any unused funds. Information on unused funds returned by the applicant on activities are not reported. "Funding Amount" does not include funds that may have been provided by other affiliated Sanofi Company Entities, (e.g., Sanofi Pasteur)

<sup>3</sup> Collaboration (Shared) Funding – is the full amount of a grant funded under an agreement with Regeneron, some or all of which may be shared between the collaborating entities.

## Independent Medical Education Grants

1<sup>st</sup> Apr 2020 – 30<sup>th</sup> Jun 2020

Sanofi US and its affiliate Genzyme Corporation are committed to supporting independent medical education activities in therapeutic areas in which the Company is involved, for healthcare professionals, patients, and consumers to improve patient care and health outcomes in therapeutic areas in which the Company is engaged. Sanofi US and Genzyme Corporation are part of the Sanofi Group, a global pharmaceutical company.

Recipient Name(s) <sup>1</sup>	Activity Title	Funding Amount <sup>2</sup>
Med-IQ, Inc.	Easing the Burden of Moderate-to-Severe Atopic Dermatitis: A Nationwide Campaign for Patients and Clinicians Utilizing Social Media and Provider Education	\$435,366 <sup>3</sup>
Clinical Care Options, LLC	Severe Eosinophilic Asthma: Key Decisions That Drive Effective Strategies with Targeted Therapies	\$63,000 <sup>3</sup>
Case Western Reserve University School of Medicine Society for Investigative Dermatology	2020 Society for Investigative Dermatology Meeting	\$50,000 <sup>3</sup>
PRIME Education, LLC	Exposing the Hidden Burdens of Atopic Dermatitis: Creating Communities of Learning to Optimize the Patient Journey	\$435,800 <sup>3</sup>
Medical Learning Institute, Inc.	PeerView Make-A-Case – Finding the Path to Improved Outcomes in Uncontrolled Persistent Asthma: Applying the Latest Clinical Evidence for Treatment Success	\$154,270 <sup>3</sup>
Continuing Education Alliance dba Practicing Clinicians Exchange	Rheumatoid Arthritis: Best Practices in Diagnosis and Treatment in the Era of Novel Agents	\$75,000
Medscape LLC	Clinical Advances in Moderate-to-Severe Atopic Dermatitis: From Practice to Outcomes - Conference Coverage	\$499,000 <sup>3</sup>
Medscape LLC	Clinical Advances in Moderate-to-Severe Atopic Dermatitis: From Practice to Outcomes - MedSims and Clinical Advances Destination Page	\$499,100 <sup>3</sup>
Integritas Communications Global Education Group	Finding the Path in Moderate-to-Severe Asthma: From Patient Identification to Collaborative Long-Term Care	\$212,150 <sup>3</sup>
Ultimate Medical Academy, LLC dba: Global Education Group	The Evolving Role of Systemic Therapies in the Management of Atopic Dermatitis: Key Principles in Patient Care and Education	\$249,100 <sup>3</sup>

<sup>1</sup> Applicant names are provided by the requestor. If applicants apply as a group for a single educational activity; all applicants may or may not be identified above. The Company funds other educational activities (including fellowships and non-physician and patient education); which are not included in this report.

<sup>2</sup> "Funding Amount" is the amount that the Company funded during Q2 2020 identified above based upon an agreement. Recipients are required to return any unused funds. Information on unused funds returned by the applicant on activities are not reported. "Funding Amount" does not include funds that may have been provided by other affiliated Sanofi Company Entities, (e.g., Sanofi Pasteur)

<sup>3</sup> Collaboration (Shared) Funding – is the full amount of a grant funded under an agreement with Regeneron, some or all of which may be shared between the collaborating entities.



## Independent Medical Education Grants

1<sup>st</sup> Apr 2020 – 30<sup>th</sup> Jun 2020

Sanofi US and its affiliate Genzyme Corporation are committed to supporting independent medical education activities in therapeutic areas in which the Company is involved, for healthcare professionals, patients, and consumers to improve patient care and health outcomes in therapeutic areas in which the Company is engaged. Sanofi US and Genzyme Corporation are part of the Sanofi Group, a global pharmaceutical company.

Recipient Name(s) <sup>1</sup>	Activity Title	Funding Amount <sup>2</sup>
Medscape LLC	Chronic Rhinosinusitis With Nasal Polyps: Simulation to Evaluated Current Practices and Improve Skills in Assessment and Treatment	\$212,875 <sup>3</sup>
Ultimate Medical Academy, LLC dba: Global Education Group	Multidisciplinary Care of Pediatric and Adolescent Patients with Moderate-to-Severe Atopic Dermatitis	\$450,000 <sup>3</sup>
Postgraduate Institute for Medicine Talem Health, LLC	2nd Annual Rural Health Clinical Congress – Advances in Management of Difficult-to-Treat Asthma: Overcoming Challenges in Rural and Underserved Settings	\$175,000 <sup>3</sup>
Postgraduate Institute for Medicine Talem Health, LLC	2nd Annual Rural Health Clinical Congress – Improving the Implementation and Adoption of Tele dermatology in Rural and Underserved Settings	\$175,000 <sup>3</sup>
Annenberg Center for Health Sciences at Eisenhower	2020 RhAPP National Conference - Virtual	\$75,000
Postgraduate Institute for Medicine	Atopic Dermatitis: A Dual Approach to Collaborative Care and Disease Control	\$370,000 <sup>3</sup>
Clinical Care Options, LLC	CCO Independent Conference Coverage: Clinical Impact of New Rheumatoid Arthritis Findings from ACR/ARP 2020	\$35,000
PRIME Education, LLC	Benchmarks and Breakthroughs in the Management of Atopic Dermatitis: Scaling Up Findings from a Systems-Based Implementation Science Initiative in AD	\$418,800 <sup>3</sup>
American Academy of Allergy, Asthma & IMMUNOology	Care of Asthma and Immune Deficient Older Adults During the COVID-19 Pandemic	\$40,000 <sup>3</sup>
Integritas Communications Global Education Group	Updates on Chronic Rhinosinusitis With Nasal Polyps: Evolving Best Practices for Patient Management	\$49,780 <sup>3</sup>
UMA MLG, LLC	Application of VA Clinical Practice Guidelines in the Management of Asthma	\$124,745 <sup>3</sup>

<sup>1</sup> Applicant names are provided by the requestor. If applicants apply as a group for a single educational activity; all applicants may or may not be identified above. The Company funds other educational activities (including fellowships and non-physician and patient education); which are not included in this report.

<sup>2</sup> "Funding Amount" is the amount that the Company funded during Q2 2020 identified above based upon an agreement. Recipients are required to return any unused funds. Information on unused funds returned by the applicant on activities are not reported. "Funding Amount" does not include funds that may have been provided by other affiliated Sanofi Company Entities, (e.g., Sanofi Pasteur)

<sup>3</sup> Collaboration (Shared) Funding – is the full amount of a grant funded under an agreement with Regeneron, some or all of which may be shared between the collaborating entities.

## Independent Medical Education Grants

1<sup>st</sup> Apr 2020 – 30<sup>th</sup> Jun 2020

Sanofi US and its affiliate Genzyme Corporation are committed to supporting independent medical education activities in therapeutic areas in which the Company is involved, for healthcare professionals, patients, and consumers to improve patient care and health outcomes in therapeutic areas in which the Company is engaged. Sanofi US and Genzyme Corporation are part of the Sanofi Group, a global pharmaceutical company.

Recipient Name(s) <sup>1</sup>	Activity Title	Funding Amount <sup>2</sup>
Integrity Continuing Education, Inc.	2020 Severe Asthma Update: Clinical Management and Key Considerations to Target Optimal Patient Care - A Social CMedia Initiative	\$237,800 <sup>3</sup>
Ultimate Medical Academy, LLC dba: Global Education Group	Fire Fight: Smothering the Flame of Type 2 Inflammation A Clinical Consults Curriculum	\$328,110 <sup>3</sup>
Ultimate Medical Academy, LLC dba: Global Education Group Purdue University	Immunological Targeting Approach for the Management of Moderate-to-Severe Asthma	\$368,500 <sup>3</sup>
UMA MLG, LLC	Addressing the Type 2 Inflammation Signature Through the Management of CRSwNP	\$239,850 <sup>3</sup>
Annenberg Center for Health Sciences at Eisenhower	Expert Perspectives: Navigating the Recent Rheumatoid Arthritis Guidelines to Achieve Disease Remission and Reduce Patient Burden	\$100,000
UT Southwestern Medical Center	Addressing the Management of Progressive Multiple Sclerosis: Utilization of an Evidence-Based Approach	\$30,000
Pharmacy Times Continuing Education	Understanding the Complexities of Multiple Sclerosis to Improve Disease Management	\$50,000
Postgraduate Institute for Medicine Letters & Sciences	8th Annual Advances in Multiple Sclerosis Research and Practice CME/CNE Conference: Breakthroughs and Emerging Evidence	\$50,000
Consortium of Multiple Sclerosis Centers	Neurofilament Light Chains as a Biomarker in Multiple Sclerosis: Consensus Conference Findings	\$55,000
National Association of Managed Care Physicians	Informed Decision-Making in the Treatment and Management of Multiple Sclerosis: Optimizing Therapeutic Switching and Sequencing Strategies	\$45,000

<sup>1</sup> Applicant names are provided by the requestor. If applicants apply as a group for a single educational activity; all applicants may or may not be identified above. The Company funds other educational activities (including fellowships and non-physician and patient education); which are not included in this report.

<sup>2</sup> "Funding Amount" is the amount that the Company funded during Q2 2020 identified above based upon an agreement. Recipients are required to return any unused funds. Information on unused funds returned by the applicant on activities are not reported. "Funding Amount" does not include funds that may have been provided by other affiliated Sanofi Company Entities, (e.g., Sanofi Pasteur)

<sup>3</sup> Collaboration (Shared) Funding – is the full amount of a grant funded under an agreement with Regeneron, some or all of which may be shared between the collaborating entities.

## Independent Medical Education Grants

1<sup>st</sup> Apr 2020 – 30<sup>th</sup> Jun 2020

Sanofi US and its affiliate Genzyme Corporation are committed to supporting independent medical education activities in therapeutic areas in which the Company is involved, for healthcare professionals, patients, and consumers to improve patient care and health outcomes in therapeutic areas in which the Company is engaged. Sanofi US and Genzyme Corporation are part of the Sanofi Group, a global pharmaceutical company.

Recipient Name(s) <sup>1</sup>	Activity Title	Funding Amount <sup>2</sup>
AKH Inc, Advancing Knowledge in Healthcare	Women's Health and Multiple Sclerosis: Management of Family Planning, Pregnancy and Postpartum Considerations	\$50,000
Postgraduate Institute for Medicine Impact Education, LLC	All Roads Lead to Change: Addressing Unmet Needs in the African American MS Community	\$75,000
UT Southwestern Medical Center	Effective Patient Education in MS Therapy Selection: Applying Clinical Understanding to Support Shared Decision Making	\$60,000
Cleveland Clinic Educational Foundation	Advancing Neurological Therapeutics 2020: Best Practices for a Future of Comprehensive Care	\$5,000
Yale University	2020 Update: What's New in the Field of Multiple Sclerosis	\$15,000
AcademicCME	Novel BTK Inhibitors: Effects on Adaptive and Innate Immunity in Multiple Sclerosis	\$90,000
National Association of Managed Care Physicians	Navigating an Increasingly Complex Treatment Paradigm in the Management of Multiple Sclerosis: Implementing Expert Switching and Sequencing Strategies	\$45,000
Consortium of Multiple Sclerosis Centers, Inc	Advances In Multiple Sclerosis Educational Website	\$50,000
Medical Learning Institute, Inc	PeerView Talks, MS Treatment Decisions Before, During and after Pregnancy: Focus on the Use of Disease-Modifying Therapies	\$50,000
Johns Hopkins University	Family Planning in MS: Improving Clinician Confidence and Addressing Patient Concerns	\$50,000
WebMD Health Corp Medscape, LLC	Myeloma Therapies of the Future: Highlights for the Oncology Nurse (ONS 2020 ISS)	\$145,000

<sup>1</sup> Applicant names are provided by the requestor. If applicants apply as a group for a single educational activity; all applicants may or may not be identified above. The Company funds other educational activities (including fellowships and non-physician and patient education); which are not included in this report.

<sup>2</sup> "Funding Amount" is the amount that the Company funded during Q2 2020 identified above based upon an agreement. Recipients are required to return any unused funds. Information on unused funds returned by the applicant on activities are not reported. "Funding Amount" does not include funds that may have been provided by other affiliated Sanofi Company Entities, (e.g., Sanofi Pasteur)

<sup>3</sup> Collaboration (Shared) Funding – is the full amount of a grant funded under an agreement with Regeneron, some or all of which may be shared between the collaborating entities.

## Independent Medical Education Grants

1<sup>st</sup> Apr 2020 – 30<sup>th</sup> Jun 2020

Sanofi US and its affiliate Genzyme Corporation are committed to supporting independent medical education activities in therapeutic areas in which the Company is involved, for healthcare professionals, patients, and consumers to improve patient care and health outcomes in therapeutic areas in which the Company is engaged. Sanofi US and Genzyme Corporation are part of the Sanofi Group, a global pharmaceutical company.

Recipient Name(s) <sup>1</sup>	Activity Title	Funding Amount <sup>2</sup>
Penn State College of Medicine Multiple Myeloma Research Foundation	Cases in Multiple Myeloma: Assessing Risk, Selecting Regimens	\$20,000
Purdue University College of Pharmacy/School of Nursing Multiple Myeloma Research Foundation	Treatment Options for Multiple Myeloma Patients Who Have Relapsed from, or are Refractory to Multiple Therapies	\$60,000
National Association of Managed Care Physicians	Novel Treatment Advances and Approaches in the Management of Relapsed/Refractory Multiple Myeloma: Expert Strategies on the Role of Emerging Therapies	\$35,000
USF Health	Prostate Cancer Update -- An Enduring Audio, Video, Podcast, Web and Mobile Interview Program for Medical Oncologists and Urologists: 2020 Edition	\$25,000
USF Health Professions Conferencing Corporation Clinical Care Options, LLC	Optimizing Multiple Myeloma Care: Expert Guidance for the Practicing Clinician	\$75,000
Clinical Care Options, LLC	New Targets and New Agents in Relapsed/Refractory Multiple Myeloma: Current Guidance and Future Perspectives	\$50,000
National Comprehensive Cancer Network	2020-2021 Monthly Oncology Tumor Boards: A Multidisciplinary Approach to Individualized Patient Care	\$7,000
Research To Practice	The Second Annual Miami General Medical Oncology Symposium — A Multitumor CME Conference for Practicing Oncologists: Prostate Cancer Module	\$30,000
CME Outfitters, LLC	Dana Farber Cancer Institute: Master Class for Oncologists 2020	\$50,000
Projects In Knowledge	Multiple Myeloma @Point of Care	\$50,000

<sup>1</sup> Applicant names are provided by the requestor. If applicants apply as a group for a single educational activity; all applicants may or may not be identified above. The Company funds other educational activities (including fellowships and non-physician and patient education); which are not included in this report.

<sup>2</sup> "Funding Amount" is the amount that the Company funded during Q2 2020 identified above based upon an agreement. Recipients are required to return any unused funds. Information on unused funds returned by the applicant on activities are not reported. "Funding Amount" does not include funds that may have been provided by other affiliated Sanofi Company Entities, (e.g., Sanofi Pasteur)

<sup>3</sup> Collaboration (Shared) Funding – is the full amount of a grant funded under an agreement with Regeneron, some or all of which may be shared between the collaborating entities.

## Independent Medical Education Grants

1<sup>st</sup> Apr 2020 – 30<sup>th</sup> Jun 2020

Sanofi US and its affiliate Genzyme Corporation are committed to supporting independent medical education activities in therapeutic areas in which the Company is involved, for healthcare professionals, patients, and consumers to improve patient care and health outcomes in therapeutic areas in which the Company is engaged. Sanofi US and Genzyme Corporation are part of the Sanofi Group, a global pharmaceutical company.

Recipient Name(s) <sup>1</sup>	Activity Title	Funding Amount <sup>2</sup>
American Academy of CME, Inc	Updates in the Management of Multiple Myeloma	\$50,000
Annenberg Center for Health Sciences at Eisenhower Clinical Care Options, LLC	Equipping Nurses to Guide Patients Through the New Therapeutic Landscape of Multiple Myeloma	\$50,000
Continuing Education Alliance dba Practicing Clinicians Exchange	Evolving Options in Metastatic Prostate Cancer	\$25,000
American Academy of CME, Inc	Nursing Perspectives in the Management of Multiple Myeloma	\$50,000
Physicians' Education Resource, LLC (PER)	2020 ASH Symposium: State of the Art Care in Relapsed/Refractory Multiple Myeloma: Novel Targets, Combinations, and Treatment Approaches	\$200,000
Plexus Communication Rush University Medical Center	VHA Oncology/Urology Clinical Forums Evolving Standards of Care in Advanced Prostate Cancer: Incorporating the Latest Therapeutic Strategies	\$60,000
i3 Health	Clinical Updates and Expert Guidance in Prostate Cancer	\$70,000
Annenberg Center for Health Sciences at Eisenhower	New Strategies for Multiple Myeloma Care: Case Studies for Nurses	\$50,000
North American Center for Continuing Medical Education (NACCME) Imedex, LLC	2020 Great Debates and Updates in Hematologic Malignancies: Innovation in Multiple Myeloma Novel Approaches for Therapeutic Success	\$40,000
Physicians' Education Resource, LLC (PER)	Uncovering the Latest Agents, Trials and Data in Multiple Myeloma: Insights from Chicago and Frankfurt	\$20,000
Physicians' Education Resource, LLC (PER)	Exploring Novel Antibody-Based Treatments for Relapsed/Refractory Multiple Myeloma: How the Experts Think and Treat	\$227,215

<sup>1</sup> Applicant names are provided by the requestor. If applicants apply as a group for a single educational activity; all applicants may or may not be identified above. The Company funds other educational activities (including fellowships and non-physician and patient education); which are not included in this report.

<sup>2</sup> "Funding Amount" is the amount that the Company funded during Q2 2020 identified above based upon an agreement. Recipients are required to return any unused funds. Information on unused funds returned by the applicant on activities are not reported. "Funding Amount" does not include funds that may have been provided by other affiliated Sanofi Company Entities, (e.g., Sanofi Pasteur)

<sup>3</sup> Collaboration (Shared) Funding – is the full amount of a grant funded under an agreement with Regeneron, some or all of which may be shared between the collaborating entities.

## Independent Medical Education Grants

1<sup>st</sup> Apr 2020 – 30<sup>th</sup> Jun 2020

Sanofi US and its affiliate Genzyme Corporation are committed to supporting independent medical education activities in therapeutic areas in which the Company is involved, for healthcare professionals, patients, and consumers to improve patient care and health outcomes in therapeutic areas in which the Company is engaged. Sanofi US and Genzyme Corporation are part of the Sanofi Group, a global pharmaceutical company.

Recipient Name(s) <sup>1</sup>	Activity Title	Funding Amount <sup>2</sup>
Research To Practice	Consensus or Controversy? Investigators Discuss Clinical Practice Patterns and Available Research Data Guiding the Management of Patients with Multiple Myeloma	\$65,000
Mua Education Inc. Global Education Group PlatformQ Health Education, LLC	2nd Annual Virtual Summit: Optimizing Uro-Oncology Care for Patients with Metastatic and Nonmetastatic Prostate Cancer	\$20,000
Plexus Communication Rush University Medical Center	Community Oncology Forums: Expert Perspectives on Navigating the Complex Treatment Landscape of Advanced Prostate Cancer	\$80,000
American Society of Clinical Oncology, Inc.	ASCO20 Virtual: Genitourinary Cancer Scientific Program and ASCO20 Virtual: Educational Program	\$30,000
Physicians' Education Resource, LLC (PER)	4th Annual Live Medical Crossfire®: Hematologic Malignancies	\$20,000
Physicians' Education Resource, LLC (PER)	Continuity in Cancer Care: Aligning Primary, Urology and Oncology Specialty Care to Improve Long Term Management of Prostate Cancer Patients	\$50,000
Physicians' Education Resource, LLC (PER)	Oncology Briefings™: Nursing Approaches to Managing Castrate-Resistant Prostate Cancer Patients in an Era of Evolving Sequencing Considerations	\$50,000
WebMD Health Corp Medscape, LLC	Advances in aTTP: How Can New Therapeutic Options Improve Patient Care?	\$181,750
Projects In Knowledge	Hemophilia A @Point of Care: Going Beyond Factor VIII to Achieve Consistent Control of Bleeding	\$75,000
Physicians' Education Resource, LLC (PER)	2020 ASH: Understanding Cold Agglutinin Disease: How do Emerging Treatment Options Have the Potential to Transform Patient Outcomes?	\$367,254
Clinical Care Options, LLC	Advances in Factor VIII Replacement for Hemophilia A	\$45,000

<sup>1</sup> Applicant names are provided by the requestor. If applicants apply as a group for a single educational activity; all applicants may or may not be identified above. The Company funds other educational activities (including fellowships and non-physician and patient education); which are not included in this report.

<sup>2</sup> "Funding Amount" is the amount that the Company funded during Q2 2020 identified above based upon an agreement. Recipients are required to return any unused funds. Information on unused funds returned by the applicant on activities are not reported. "Funding Amount" does not include funds that may have been provided by other affiliated Sanofi Company Entities, (e.g., Sanofi Pasteur)

<sup>3</sup> Collaboration (Shared) Funding – is the full amount of a grant funded under an agreement with Regeneron, some or all of which may be shared between the collaborating entities.

## Independent Medical Education Grants

1<sup>st</sup> Apr 2020 – 30<sup>th</sup> Jun 2020

Sanofi US and its affiliate Genzyme Corporation are committed to supporting independent medical education activities in therapeutic areas in which the Company is involved, for healthcare professionals, patients, and consumers to improve patient care and health outcomes in therapeutic areas in which the Company is engaged. Sanofi US and Genzyme Corporation are part of the Sanofi Group, a global pharmaceutical company.

Recipient Name(s) <sup>1</sup>	Activity Title	Funding Amount <sup>2</sup>
Medical Education Resources, Inc. National Hemophilia Foundation	ManagedCareHemo.com Presents: Advanced Cases in Cost Optimization and Care Coordination for Managed Care and Specialty Pharmacy	\$50,000
Clinical Care Options, LLC	Contemporary Management of Hemophilia A: Expert Guidance to Improve Patient Outcomes	\$150,000 <sup>3</sup>
The France Foundation International Society on Thrombosis & Hemostasis	Diagnosing and Managing TTP: Supporting Implementation of ISTH Guidelines	\$250,000
Postgraduate Institute for Medicine (PIM) TotalCME, Inc.	ISTH TV 2020: Congress Analysis in Hemophilia - Integrating Data into Clinical Practice in the Era of COVID-19	\$29,967

<sup>1</sup> Applicant names are provided by the requestor. If applicants apply as a group for a single educational activity; all applicants may or may not be identified above. The Company funds other educational activities (including fellowships and non-physician and patient education); which are not included in this report.

<sup>2</sup> "Funding Amount" is the amount that the Company funded during Q2 2020 identified above based upon an agreement. Recipients are required to return any unused funds. Information on unused funds returned by the applicant on activities are not reported. "Funding Amount" does not include funds that may have been provided by other affiliated Sanofi Company Entities, (e.g., Sanofi Pasteur)

<sup>3</sup> Collaboration (Shared) Funding – is the full amount of a grant funded under an agreement with Regeneron, some or all of which may be shared between the collaborating entities.

## Independent Medical Education Grants

1<sup>st</sup> Jul 2020 – 30<sup>th</sup> Sep 2020

Sanofi US and its affiliate Genzyme Corporation are committed to supporting independent medical education activities in therapeutic areas in which the Company is involved, for healthcare professionals, patients, and consumers to improve patient care and health outcomes in therapeutic areas in which the Company is engaged. Sanofi US and Genzyme Corporation are part of the Sanofi Group, a global pharmaceutical company.

Recipient Name(s) <sup>1</sup>	Activity Title	Funding Amount <sup>2</sup>
International Transplant Nurses Society	ITNS 2020 Transplant Nursing Symposium, Genomics in Transplant: The Universal Code for Care	\$10,000
Med Learning Group	Reducing the Burden of Atrial Fibrillation: A Whiteboard Animated Tour of Antiarrhythmic Drugs for Cardiologists	\$399,425
NACCME, LLC.	Cardiology Virtual Grand Rounds: Improving Outcomes in Atrial Fibrillation with Optimal Antiarrhythmic Approaches	\$100,000
Affinity CE/PESG LDRTC	GRIDS 2020-Virtual Summit Lysosomal Storage Disorders – Disease Mechanisms, and Patient Care and Management in the Midst of COVID-19 Crisis	\$85,000
Ebix, Inc. touchIME	Pompe Disease: Expanding Manifestations and Evolving Management	\$125,000
Every Life Foundation for Rare Diseases	12th Annual Rare Disease Scientific Workshop COVID-19 Mitigation Strategies in Rare Disease Therapy Delivery and Development: Exchanging Best Practices - Moving to Permanent Solutions	\$15,000
Annenberg Center for Health Sciences at Eisenhower	An Interactive Guide to the Underdiagnosed, Underestimated but Treatable Metabolic Disorders	\$80,000
Inter. Parkinson's and Movement Disorder Society	A Comprehensive Review of Movement Disorders for the Clinical Practitioner	\$5,000
Greenwood Genetic Center	Clinical Research Mini-Rotation for Genetic Counseling Students	\$19,188
Columbia University Irving Medical Center Amedo LLC	Medical Genetics for Internal Medicine	\$50,000
American Association of Nurse Practitioners	Early Diagnosis and Management of Rheumatoid Arthritis	\$40,000

<sup>1</sup> Applicant names are provided by the requestor. If applicants apply as a group for a single educational activity; all applicants may or may not be identified above. The Company funds other educational activities (including fellowships and non-physician and patient education); which are not included in this report.

<sup>2</sup> "Funding Amount" is the amount that the Company funded during Q3 2020 identified above based upon an agreement. Recipients are required to return any unused funds. Information on unused funds returned by the applicant on activities are not reported. "Funding Amount" does not include funds that may have been provided by other affiliated Sanofi Company Entities, (e.g., Sanofi Pasteur)

<sup>3</sup> Collaboration (Shared) Funding – is the full amount of a grant funded under an agreement with Regeneron, some or all of which may be shared between the collaborating entities.



## Independent Medical Education Grants

1<sup>st</sup> Jul 2020 – 30<sup>th</sup> Sep 2020

Sanofi US and its affiliate Genzyme Corporation are committed to supporting independent medical education activities in therapeutic areas in which the Company is involved, for healthcare professionals, patients, and consumers to improve patient care and health outcomes in therapeutic areas in which the Company is engaged. Sanofi US and Genzyme Corporation are part of the Sanofi Group, a global pharmaceutical company.

Recipient Name(s) <sup>1</sup>	Activity Title	Funding Amount <sup>2</sup>
National Association of Pediatric Nurse Practitioners	NAPNAP Virtual Conference (breakout presentation): Navigating the Roadmap for Treating Pediatric Asthma: Latest Guidelines and Strategies	\$5,500 <sup>3</sup>
Oakstone Publishing, LLC Answers in CME Inc.	Calming the Beast that is AD Burden: Evaluating the Latest Evidence for Biologic Therapies in Pediatric and Adolescent Patients	\$158,750 <sup>3</sup>
Oakstone Publishing, LLC Answers in CME Inc.	Highlights of Individualizing Care With Biologics in Moderate to Severe Asthma	\$360,000 <sup>3</sup>
Advancing Knowledge in Healthcare RMEI	Clinical Convergence®: Creating a Framework for Personalized Management in the Treatment of Children with Asthma	\$174,890 <sup>3</sup>
Ultimate Medical Academy, LLC dba: Global Education Group	Coming Up for Air to Manage Patients with Severe Asthma	\$181,605 <sup>3</sup>
Medical Learning Institute Inc	PeerView inMotion - Navigating the Relationship Between Type 2 Inflammation and Uncontrolled, Moderate-to-Severe Asthma: Identifying Eligible Patients for Targeted Biologic Therapy	\$176,670 <sup>3</sup>
University of Louisville School of Medicine University of Louisville Research Foundation, Inc.	My Virtual Clinical Community of Practice (MyCCOP.com) –“Rheums with a New View”	\$15,000
Institute for Continuing Healthcare Education	COVID-19 and Treatment of Moderate-to-Severe Atopic Dermatitis: The Role of Systemic Agents	\$80,550 <sup>3</sup>
Rheumatology Nurses Society	13th Annual 2020 RNS Virtual Conference	\$15,000
Medical Learning Institute Inc	PeerView inPlay, Understanding the Relationship Between Type 2 Inflammation, Atopic Diseases and Treatment Selection: Practical Strategies for the Healthcare Team to Improve Patient Care	\$171,400 <sup>3</sup>

<sup>1</sup> Applicant names are provided by the requestor. If applicants apply as a group for a single educational activity; all applicants may or may not be identified above. The Company funds other educational activities (including fellowships and non-physician and patient education); which are not included in this report.

<sup>2</sup> “Funding Amount” is the amount that the Company funded during Q3 2020 identified above based upon an agreement. Recipients are required to return any unused funds. Information on unused funds returned by the applicant on activities are not reported. “Funding Amount” does not include funds that may have been provided by other affiliated Sanofi Company Entities, (e.g., Sanofi Pasteur)

<sup>3</sup> Collaboration (Shared) Funding – is the full amount of a grant funded under an agreement with Regeneron, some or all of which may be shared between the collaborating entities.

## Independent Medical Education Grants

1<sup>st</sup> Jul 2020 – 30<sup>th</sup> Sep 2020

Sanofi US and its affiliate Genzyme Corporation are committed to supporting independent medical education activities in therapeutic areas in which the Company is involved, for healthcare professionals, patients, and consumers to improve patient care and health outcomes in therapeutic areas in which the Company is engaged. Sanofi US and Genzyme Corporation are part of the Sanofi Group, a global pharmaceutical company.

Recipient Name(s) <sup>1</sup>	Activity Title	Funding Amount <sup>2</sup>
Health Science Educational Institute	Addressing the Constellation of Symptoms in Asthma- Raising Awareness to Improve Outcomes	\$4,500 <sup>3</sup>
Physicians Continuing Education, Corporation	Challenges & Considerations in Atopic Dermatitis Management	\$84,690 <sup>3</sup>
Integrity Continuing Education, Inc. UMA Education Inc. dba Global Education Group	2020 GOLD and GINA International COPD and Asthma Live Virtual and On-demand Conference	\$25,000 <sup>3</sup>
Physicians' Education Resource, LLC (PER)	Advances In: Best Practices in RA Management – Applying the Evidence to Optimize Treatment Decision-Making	\$113,952
Annenberg Center for Health Sciences at Eisenhower	Poster Perspectives: Research Developments in Rheumatoid Arthritis: ACR 2020	\$25,000
Projects In Knowledge	BreakingMED: News - Views - Analysis in Multiple Sclerosis in 2020	\$50,000
AcademicCME, LLC.	The Virtual Live-Streamed Pre-ACTRIMS/ECTRIMS 2020 Multiple Sclerosis Course	\$20,000
Postgraduate Institute for Medicine (PIM) Efficient LLC	Networks in Neurology: A Virtual Collaboration of Specialists and Practicing Neurologists on the Effective Integration of New Agents and Strategies for Multiple Sclerosis	\$50,000
Projects In Knowledge	Morning Commute Podcast Series on Multiple Sclerosis	\$98,000
Vindico Medical Education, LLC	Multiple Sclerosis in Women: Adaptation of Management Strategies for Family Planning and Beyond	\$75,000
National Association of Managed Care Physicians	Managing Clinical and Cost Outcomes in Multiple Sclerosis: Utilizing Data to Make Informed Decisions in Managed Care	\$60,000

<sup>1</sup> Applicant names are provided by the requestor. If applicants apply as a group for a single educational activity; all applicants may or may not be identified above. The Company funds other educational activities (including fellowships and non-physician and patient education); which are not included in this report.

<sup>2</sup> "Funding Amount" is the amount that the Company funded during Q3 2020 identified above based upon an agreement. Recipients are required to return any unused funds. Information on unused funds returned by the applicant on activities are not reported. "Funding Amount" does not include funds that may have been provided by other affiliated Sanofi Company Entities, (e.g., Sanofi Pasteur)

<sup>3</sup> Collaboration (Shared) Funding – is the full amount of a grant funded under an agreement with Regeneron, some or all of which may be shared between the collaborating entities.

## Independent Medical Education Grants

1<sup>st</sup> Jul 2020 – 30<sup>th</sup> Sep 2020

Sanofi US and its affiliate Genzyme Corporation are committed to supporting independent medical education activities in therapeutic areas in which the Company is involved, for healthcare professionals, patients, and consumers to improve patient care and health outcomes in therapeutic areas in which the Company is engaged. Sanofi US and Genzyme Corporation are part of the Sanofi Group, a global pharmaceutical company.

Recipient Name(s) <sup>1</sup>	Activity Title	Funding Amount <sup>2</sup>
CME Outfitters, LLC	Finding your Footing in the Shifting Landscape of Multiple Sclerosis	\$50,000
National Association of Managed Care Physicians	Personalized Treatment Strategies in the Management of Castration-Resistant Prostate Cancer	\$35,000
i3 Health	New Data and Clinical Perspectives on the Treatment of Metastatic Hormone-Sensitive Prostate Cancer	\$125,000
AXIS Medical Education	Advanced Practice Perspectives on Preventing and Managing Tumor Lysis Syndrome and Neutropenia in CLL	\$64,475
National Association of Managed Care Physicians	New Frontiers in the Treatment and Management of Relapsed/Refractory Multiple Myeloma: A Closer Look at the Role of New and Emerging Therapies	\$45,000
WebMD Health Corp Medscape, LLC	Clinical Advances in Multiple Myeloma	\$500,000
WebMD Health Corp Medscape, LLC	Novel Approaches for Managing Patients with Multiple Myeloma	\$75,000
North America Center for Continuing Education, LLC.	Oncology Clinical Pathways Congress 2020: Navigating Complex Treatment Landscapes in Oncology: Developing Clinical Pathways in Prostate Cancer	\$25,000
American Urological Association	2020 AUA Summer Webinar Series: Genitourinary Oncology	\$150,000
American Urological Association	AUA Live	\$15,000
Research To Practice	Oncology Today with Dr Neil Love — Recently Approved Agents in Multiple Myeloma Edition	\$50,000
Medscape, LLC	Chemotherapy in the Real World for Metastatic Prostate Cancer Management	\$159,500

<sup>1</sup> Applicant names are provided by the requestor. If applicants apply as a group for a single educational activity; all applicants may or may not be identified above. The Company funds other educational activities (including fellowships and non-physician and patient education); which are not included in this report.

<sup>2</sup> "Funding Amount" is the amount that the Company funded during Q3 2020 identified above based upon an agreement. Recipients are required to return any unused funds. Information on unused funds returned by the applicant on activities are not reported. "Funding Amount" does not include funds that may have been provided by other affiliated Sanofi Company Entities, (e.g., Sanofi Pasteur)

<sup>3</sup> Collaboration (Shared) Funding – is the full amount of a grant funded under an agreement with Regeneron, some or all of which may be shared between the collaborating entities.

## Independent Medical Education Grants

1<sup>st</sup> Jul 2020 – 30<sup>th</sup> Sep 2020

Sanofi US and its affiliate Genzyme Corporation are committed to supporting independent medical education activities in therapeutic areas in which the Company is involved, for healthcare professionals, patients, and consumers to improve patient care and health outcomes in therapeutic areas in which the Company is engaged. Sanofi US and Genzyme Corporation are part of the Sanofi Group, a global pharmaceutical company.

Recipient Name(s) <sup>1</sup>	Activity Title	Funding Amount <sup>2</sup>
National Comprehensive Cancer Network	NCCN Nursing Forum: Advancing Oncology Nursing in Hematologic Malignancies	\$13,310
PRIME Education, LLC	Targeted Therapies in Relapsed/Refractory Multiple Myeloma: Patient-Centered Selection and Sequencing	\$50,000
Amedco CANCERNET, LLC	Changing Landscape of Treatment Options for Multiple Myeloma Antibodies, Combination Therapies and CAR T-cell Therapies	\$25,000
Surgent PharmCon LLC	The Next Steps in Multiple Myeloma: A Review of New and Emerging Treatment Options	\$7,600
Practicing Clinicians Exchange Continuing Education Alliance, LLC	The Evolving Landscape of Prostate Cancer Management	\$125,000
Plexus Communication Rush University Medical Center	Navigating the Continuum of Care for Advanced Prostate Cancer (mHSPC, CRPC)	\$80,000
Research To Practice	Year in Review — Prostate Cancer Module	\$55,000
Baylor College of Medicine	The 2020 Virtual Innovations in Urologic Practice	\$10,000
Physicians' Education Resource, LLC (PER)	Medical Crossfire®: Navigating Treatment Decisions in Advanced Prostate Cancer as New Options Emerge	\$75,000
North American Center for Continuing Medical Education (NACCME LLC) Imedex, LLC	Personalized Precision Approaches in Multiple Myeloma: Novel Therapeutic Targets and Combination Strategies	\$110,000
Medscape, LLC	ASCO GU 2021 ISS: Take the Challenge: Putting your Practice for Prostate Cancer to the Test	\$75,000

<sup>1</sup> Applicant names are provided by the requestor. If applicants apply as a group for a single educational activity; all applicants may or may not be identified above. The Company funds other educational activities (including fellowships and non-physician and patient education); which are not included in this report.

<sup>2</sup> "Funding Amount" is the amount that the Company funded during Q3 2020 identified above based upon an agreement. Recipients are required to return any unused funds. Information on unused funds returned by the applicant on activities are not reported. "Funding Amount" does not include funds that may have been provided by other affiliated Sanofi Company Entities, (e.g., Sanofi Pasteur)

<sup>3</sup> Collaboration (Shared) Funding – is the full amount of a grant funded under an agreement with Regeneron, some or all of which may be shared between the collaborating entities.

## Independent Medical Education Grants

1<sup>st</sup> Jul 2020 – 30<sup>th</sup> Sep 2020

Sanofi US and its affiliate Genzyme Corporation are committed to supporting independent medical education activities in therapeutic areas in which the Company is involved, for healthcare professionals, patients, and consumers to improve patient care and health outcomes in therapeutic areas in which the Company is engaged. Sanofi US and Genzyme Corporation are part of the Sanofi Group, a global pharmaceutical company.

Recipient Name(s) <sup>1</sup>	Activity Title	Funding Amount <sup>2</sup>
The Board of Regents of the University of Nebraska	ASCO 2020 Satellite Symposium: The Expanding Role of Immunotherapy for the Treatment of Multiple Myeloma – Focus on Antibodies, Antibody-Drug Conjugates and CAR T-Cells	\$75,000
Physicians' Education Resource, LLC (PER)	Live Video Webcast: Cancer Care in the COVID-19 Era: Assessing the Impact of Racial and Ethnic Disparities	\$25,000
The Board of Regents of the University of Nebraska	2020 Leadership Education and Development (LEAD): Enriching Experiences for Women in Hematology and Oncology	\$15,000
University of Cincinnati	Personalizing Prophylaxis for Hemophilia A and B: A New Era in Treatment and Management	\$59,912
Physicians' Education Resource, LLC (PER)	Advances In™ Hematology: New Frontiers in the Treatment of TTP	\$106,025
Postgraduate Institute for Medicine PlatformQ Health Education, LLC	Spotlight on Rare Cancers: Advancing Novel Therapy and Patient Centered Management	\$50,000
AKH Inc., Advancing Knowledge in Healthcare	It's Not "One Size Fits All": Addressing Complications and Barriers to Unlock Individualized Treatment and Management for Patients with Hemophilia A	\$60,000

<sup>1</sup> Applicant names are provided by the requestor. If applicants apply as a group for a single educational activity; all applicants may or may not be identified above. The Company funds other educational activities (including fellowships and non-physician and patient education); which are not included in this report.

<sup>2</sup> "Funding Amount" is the amount that the Company funded during Q3 2020 identified above based upon an agreement. Recipients are required to return any unused funds. Information on unused funds returned by the applicant on activities are not reported. "Funding Amount" does not include funds that may have been provided by other affiliated Sanofi Company Entities, (e.g., Sanofi Pasteur)

<sup>3</sup> Collaboration (Shared) Funding – is the full amount of a grant funded under an agreement with Regeneron, some or all of which may be shared between the collaborating entities.

## Independent Medical Education Grants

**1<sup>st</sup> Oct 2020 – 31<sup>st</sup> Dec 2020**

Sanofi US and its affiliate Genzyme Corporation are committed to supporting independent medical education activities in therapeutic areas in which the Company is involved, for healthcare professionals, patients, and consumers to improve patient care and health outcomes in therapeutic areas in which the Company is engaged. Sanofi US and Genzyme Corporation are part of the Sanofi Group, a global pharmaceutical company.

Recipient Name(s) <sup>1</sup>	Activity Title	Funding Amount <sup>2</sup>
University of Illinois at Chicago College of Pharmacy	Illinois Transplant Pharmacists Association Symposium	\$8,000
American Society of Transplant Surgeons	ASTS 21st Annual State of the Art Winter Symposium	\$100,000
Medscape, LLC	Recent AF: Is an Earlier Rhythm Control Strategy the New Paradigm?	\$314,125
The Medical College of Wisconsin, Inc Physicians' Education Resource, LLC (PER)	2021 TCT: Optimizing the Use of Stem Cell Mobilization in Patients With Multiple Myeloma and Non-Hodgkin's Lymphoma	\$313,750
Washington University Seattle Children's Hospital	Clinical Laboratory Stewardship: Tips, Tricks and Tools to Benefit Patients, Labs and Payers	\$12,000
Muscular Dystrophy Association	What's New in Pompe Speaker Slide Deck	\$60,000
Physicians' Education Resource, LLC (PER)	Clinical Consultations: Streamlining the Pathway from Diagnosis to Treatment in Patients with MPS I	\$130,525
Cedars-Sinai	10th Annual Symposium on Lysosomal Storage Disorders	\$20,000
National Kidney Foundation	Treating the Whole Patient in Fabry Disease: Early Identification and Coordinated Treatment	\$299,400
AKH, Inc. Catalyst Medical Education, LLC	Changing Tides in the Management of Niemann-Pick: Emerging Treatments and Strategies to Improve Diagnosis (WORLD 2021)	\$199,300
Regents University of California Los Angeles	Fabry Disease : What a Healthcare Provider Should Know	\$63,000

<sup>1</sup> Applicant names are provided by the requestor. If applicants apply as a group for a single educational activity; all applicants may or may not be identified above. The Company funds other educational activities (including fellowships and non-physician and patient education); which are not included in this report.

<sup>2</sup> "Funding Amount" is the amount that the Company funded during Q4 2020 identified above based upon an agreement. Recipients are required to return any unused funds. Information on unused funds returned by the applicant on activities are not reported. "Funding Amount" does not include funds that may have been provided by other affiliated Sanofi Company Entities, (e.g., Sanofi Pasteur)

<sup>3</sup> Collaboration (Shared) Funding – is the full amount of a grant funded under an agreement with Regeneron, some or all of which may be shared between the collaborating entities.

## Independent Medical Education Grants

1<sup>st</sup> Oct 2020 – 31<sup>st</sup> Dec 2020

Sanofi US and its affiliate Genzyme Corporation are committed to supporting independent medical education activities in therapeutic areas in which the Company is involved, for healthcare professionals, patients, and consumers to improve patient care and health outcomes in therapeutic areas in which the Company is engaged. Sanofi US and Genzyme Corporation are part of the Sanofi Group, a global pharmaceutical company.

Recipient Name(s) <sup>1</sup>	Activity Title	Funding Amount <sup>2</sup>
National Association For Continuing Education	Caring for Patients with Atopic Dermatitis: Incorporating Pathophysiology into a Comprehensive Management Plan	\$285,500 <sup>3</sup>
Integritas Communications Global Education Group	Where Are We Now in Moderate-to-Severe Asthma? From Comprehensive Patient Evaluations to Individualized Evidence-Based Care	\$200,000 <sup>3</sup>
Vindico Medical Education, LLC	Gaining Control in Moderate to Severe Asthma: Test Your Confidence with Game On!	\$98,610 <sup>3</sup>
Medical Learning Institute Inc	PeerView Make-A-Case – Easing the Burden of Chronic Rhinosinusitis with Nasal Polyps on Patient Quality of Life: Exploring the Role of Novel and Emerging Targeted Biologic Therapies	\$183,520 <sup>3</sup>
Pri-Med Institute, LLC	Treating More Than Just an Itch: Updates on Atopic Dermatitis for the Primary Care Provider	\$337,152 <sup>3</sup>
Haymarket Medical Education	Improving the Treatment of Severe Asthma in the Biologics Age: An Interdisciplinary Approach to Optimal Patient Outcomes	\$127,789 <sup>3</sup>
University of Cincinnati	Maui Derm Connect	\$10,000 <sup>3</sup>
PRIME Education, LLC	6th Annual Regional Seminars for Providers in Federal and Public Health Sectors: Interprofessional Education on Atopic Dermatitis	\$195,500 <sup>3</sup>
Creighton University Health Sciences Continuing Education Physicians Continuing Education, Corporation	Skin of Color Update Virtual 2020	\$10,000 <sup>3</sup>
American College of Rheumatology	2020 ACR Convergence	\$35,000

<sup>1</sup> Applicant names are provided by the requestor. If applicants apply as a group for a single educational activity; all applicants may or may not be identified above. The Company funds other educational activities (including fellowships and non-physician and patient education); which are not included in this report.

<sup>2</sup> "Funding Amount" is the amount that the Company funded during Q4 2020 identified above based upon an agreement. Recipients are required to return any unused funds. Information on unused funds returned by the applicant on activities are not reported. "Funding Amount" does not include funds that may have been provided by other affiliated Sanofi Company Entities, (e.g., Sanofi Pasteur)

<sup>3</sup> Collaboration (Shared) Funding – is the full amount of a grant funded under an agreement with Regeneron, some or all of which may be shared between the collaborating entities.

## Independent Medical Education Grants

1<sup>st</sup> Oct 2020 – 31<sup>st</sup> Dec 2020

Sanofi US and its affiliate Genzyme Corporation are committed to supporting independent medical education activities in therapeutic areas in which the Company is involved, for healthcare professionals, patients, and consumers to improve patient care and health outcomes in therapeutic areas in which the Company is engaged. Sanofi US and Genzyme Corporation are part of the Sanofi Group, a global pharmaceutical company.

Recipient Name(s) <sup>1</sup>	Activity Title	Funding Amount <sup>2</sup>
Medscape LLC	CRSwNP: Micro-Learning Approach to Advancing Management	\$231,500 <sup>3</sup>
Potomac Center for Medical Education	Telemedicine in Asthma Management: What Clinicians Need to Know	\$148,300 <sup>3</sup>
University of Nevada, Reno School of Medicine Foundation for Research & Education	2020 Fall Clinical and 2021 Winter Clinical Dermatology Conferences Live and Enduring CME Satellite: Long-Term Management of Moderate-to-Severe Atopic Dermatitis: What You Really Need to Know	\$200,000 <sup>3</sup>
UMA MLG, LLC	Using Managed Care to Minimize the Burden of Moderate-to-Severe Atopic Dermatitis in Pediatric and Adult Patients	\$229,950 <sup>3</sup>
UMA MLG, LLC	Targeted Approaches to the Management of Moderate-to-Severe Asthma: Implications for Managed Care – An Innovative View	\$229,950 <sup>3</sup>
Pharmacy Times Continuing Education	Effective Management of Moderate to Severe Pediatric Atopic Dermatitis: Applying Evidence Based-Case Reviews in Practice	\$79,383 <sup>3</sup>
Postgraduate Institute for Medicine	Chronic Rhinosinusitis with Nasal Polyps Misperceptions and Solutions: Patient and Provider Perspectives	\$299,825 <sup>3</sup>
AKH, Inc. Tarsus Cardio LiVDerm	Masters of Pediatric Dermatology 2021	\$10,000 <sup>3</sup>
Physicians' Education Resource, LLC (PER)	PER® Power Hour: Optimizing Care in Adolescent and Pediatric Patients with Atopic Dermatitis	\$200,150 <sup>3</sup>
UMA MLG, LLC	The New Paradigm in the Management of Moderate-to-Severe Atopic Dermatitis: Improving Symptoms and Quality of Life with Systemic Therapies A Part of the THRIVE – Atopic Dermatitis Initiative	\$269,860 <sup>3</sup>
Oakstone Publishing, LLC Answers in CME Inc.	Getting Real with Pediatric Atopic Dermatitis: Approaches to Optimizing the Management of Moderate-to-Severe Disease in the Real World	\$143,750 <sup>3</sup>

<sup>1</sup> Applicant names are provided by the requestor. If applicants apply as a group for a single educational activity; all applicants may or may not be identified above. The Company funds other educational activities (including fellowships and non-physician and patient education); which are not included in this report.

<sup>2</sup> "Funding Amount" is the amount that the Company funded during Q4 2020 identified above based upon an agreement. Recipients are required to return any unused funds. Information on unused funds returned by the applicant on activities are not reported. "Funding Amount" does not include funds that may have been provided by other affiliated Sanofi Company Entities, (e.g., Sanofi Pasteur)

<sup>3</sup> Collaboration (Shared) Funding – is the full amount of a grant funded under an agreement with Regeneron, some or all of which may be shared between the collaborating entities.



## Independent Medical Education Grants

1<sup>st</sup> Oct 2020 – 31<sup>st</sup> Dec 2020

Sanofi US and its affiliate Genzyme Corporation are committed to supporting independent medical education activities in therapeutic areas in which the Company is involved, for healthcare professionals, patients, and consumers to improve patient care and health outcomes in therapeutic areas in which the Company is engaged. Sanofi US and Genzyme Corporation are part of the Sanofi Group, a global pharmaceutical company.

Recipient Name(s) <sup>1</sup>	Activity Title	Funding Amount <sup>2</sup>
UMA MLG, LLC	Moderate-to-Severe Atopic Dermatitis: Targeting the Underlying Inflammatory Processes to Improve Patient Outcomes. A Part of the Thrive – Atopic Dermatitis Initiative	\$300,000 <sup>3</sup>
University of Cincinnati	Maui Derm 2021	\$10,000 <sup>3</sup>
AKH, Inc. Tarsus Cardio LiVDerm	Atopic Dermatitis Digital Highlights Hub	\$20,000 <sup>3</sup>
European Forum for Research and Education in Aller	Practice-based Treatment Options and Outcomes with Biologics in CRSwNP and Asthma	\$60,000 <sup>3</sup>
Oakstone Publishing, LLC Answers in CME Inc.	Intensifying the Identification and Treatment of Moderate-to-Severe AD: A Concerted Look at Aligning Patients and Therapy	\$150,000 <sup>3</sup>
Medscape LLC	The Atopic Dermatitis Future is So Bright	\$200,000 <sup>3</sup>
Ultimate Medical Academy, LLC dba: Global Education Group	A Breath of Fresh Air in Pediatric Asthma: Shared Decision Making in the Era of Biologics	\$325,763 <sup>3</sup>
Haymarket Medical Education	Striving for Control: Taming Moderate to Severe Childhood Asthma in the Biologics Age Symposium at AAAAI 2021 Annual Meeting - a Virtual Event	\$308,615 <sup>3</sup>
PRIME Education, LLC	Essential Updates for Specialty Pharmacy on Evolving Therapies for Moderate to Severe Asthma Across the Lifespan	\$228,705 <sup>3</sup>
Oakstone Publishing, LLC Touch Medical Media	Paving the Way for Optimal Disease Control in Moderate-to-Severe Type 2 Asthma	\$222,140 <sup>3</sup>
Creighton University Health Sciences Continuing Education Physicians Continuing Education, Corp.	ODAC Dermatology, Aesthetic and Surgical Conference 2021	\$10,000 <sup>3</sup>

<sup>1</sup> Applicant names are provided by the requestor. If applicants apply as a group for a single educational activity; all applicants may or may not be identified above. The Company funds other educational activities (including fellowships and non-physician and patient education); which are not included in this report.

<sup>2</sup> "Funding Amount" is the amount that the Company funded during Q4 2020 identified above based upon an agreement. Recipients are required to return any unused funds. Information on unused funds returned by the applicant on activities are not reported. "Funding Amount" does not include funds that may have been provided by other affiliated Sanofi Company Entities, (e.g., Sanofi Pasteur)

<sup>3</sup> Collaboration (Shared) Funding – is the full amount of a grant funded under an agreement with Regeneron, some or all of which may be shared between the collaborating entities.

## Independent Medical Education Grants

1<sup>st</sup> Oct 2020 – 31<sup>st</sup> Dec 2020

Sanofi US and its affiliate Genzyme Corporation are committed to supporting independent medical education activities in therapeutic areas in which the Company is involved, for healthcare professionals, patients, and consumers to improve patient care and health outcomes in therapeutic areas in which the Company is engaged. Sanofi US and Genzyme Corporation are part of the Sanofi Group, a global pharmaceutical company.

Recipient Name(s) <sup>1</sup>	Activity Title	Funding Amount <sup>2</sup>
Office of Continuing Medical & Interprofessional Education at Penn Medicine	Immunotherapy for Neurologic Disorders	\$5,000
Postgraduate Institute for Medicine Impact Education, LLC	Multiple Sclerosis Management Optimization Strategies for Managed Care and Specialty Pharmacy Professionals	\$5,000
Medical Learning Institute Inc	Exploring the Rationale, Results and Real-World Clinical Potential of BTK Inhibitors in the Management of Multiple Sclerosis	\$215,600
Specialty Pharma Education Center	An Overview of Multiple Sclerosis: Advances in Care for Optimized Outcomes	\$49,750
Consortium of Multiple Sclerosis Centers	In Case You Missed It: Recent Clinical Updates in the Management of Multiple Sclerosis	\$40,251
AcademicCME	Advanced Curriculum for Multiple Sclerosis 2021	\$75,000
WebMD Health Corp Medscape, LLC	13th Annual Hematologic Malignancies Demystified: A Critical Appraisal of Data from 2020	\$50,000
American Urological Association	2020 AUA Expert Exchange Podcast: Discussions about Managing GU Cancer	\$50,000
Research To Practice	Current Concepts and Recent Advances in Cancer Care: A Live Virtual CME Summit Hosted in Conjunction with Florida Cancer Specialists — Genitourinary Cancers Module	\$10,000
Physicians' Education Resource, LLC (PER)	Cancer Summaries and Commentaries™ Update from Madrid on the Treatment of Breast Cancer, Lung Cancer and Genitourinary Malignancies	\$25,000
Research To Practice	Oncology Today with Dr Neil Love — Special Edition: Key Presentations from the 62nd American Society of Hematology (ASH) Annual Meeting -- Multiple Myeloma, Waldenström Macroglobulinemia and Amyloidosis Issue	\$20,000

<sup>1</sup> Applicant names are provided by the requestor. If applicants apply as a group for a single educational activity; all applicants may or may not be identified above. The Company funds other educational activities (including fellowships and non-physician and patient education); which are not included in this report.

<sup>2</sup> "Funding Amount" is the amount that the Company funded during Q4 2020 identified above based upon an agreement. Recipients are required to return any unused funds. Information on unused funds returned by the applicant on activities are not reported. "Funding Amount" does not include funds that may have been provided by other affiliated Sanofi Company Entities, (e.g., Sanofi Pasteur)

<sup>3</sup> Collaboration (Shared) Funding – is the full amount of a grant funded under an agreement with Regeneron, some or all of which may be shared between the collaborating entities.

## Independent Medical Education Grants

1<sup>st</sup> Oct 2020 – 31<sup>st</sup> Dec 2020

Sanofi US and its affiliate Genzyme Corporation are committed to supporting independent medical education activities in therapeutic areas in which the Company is involved, for healthcare professionals, patients, and consumers to improve patient care and health outcomes in therapeutic areas in which the Company is engaged. Sanofi US and Genzyme Corporation are part of the Sanofi Group, a global pharmaceutical company.

Recipient Name(s) <sup>1</sup>	Activity Title	Funding Amount <sup>2</sup>
Physicians' Education Resource, LLC (PER)	2021 ASCO GU ISS: Optimizing Treatment Throughout the Prostate Cancer Continuum: How the Experts Think and Treat	\$100,000
Postgraduate Institute for Medicine Total CME	Conference Coverage: Highlights in Multiple Myeloma from the 62nd ASH Annual Meeting Integrating Data into Clinical Practice	\$39,996
The Board of Regents of the University of Nebraska	2020 Podium to Practice: Recent Clinical Trial Updates of Current and Emerging Approaches for the Treatment of Relapsed/Refractory Multiple Myeloma	\$25,000
Med-IQ, Inc.	Multiple Myeloma Newsflash: Emerging Data from the 2020 ASH Annual Meeting	\$75,000
Purdue University College of Pharmacy/School of Nursing Multiple Myeloma Research Foundation	Immunotherapy for Multiple Myeloma: From Antibodies to CAR T-Cell Therapy	\$100,000
Projects In Knowledge	Morning Commute: Podcast Series on Multiple Myeloma	\$50,000
Medical Education Resources, Inc.	29th Annual Perspectives in Urology: Point-Counterpoint (PCP 29)	\$10,000
Physicians' Education Resource, LLC (PER)	A New Wave of Progress in Relapsed/Refractory Multiple Myeloma: Global Perspectives on Antibody-Based Treatment Strategies	\$299,850
WebMD Health Corp Medscape, LLC	2021 ONS ISS: Interactive Myeloma Clinic: Nursing Pearls for Current and Emerging Therapies	\$60,004
Physicians' Education Resource, LLC (PER)	New York GU™: 14th Annual Interdisciplinary Prostate Cancer Congress® and Other Genitourinary Malignancies	\$50,000
Research To Practice	Cases from the Community: Investigators Discuss Emerging Research and Actual Patients with Prostate Cancer	\$65,000

<sup>1</sup> Applicant names are provided by the requestor. If applicants apply as a group for a single educational activity; all applicants may or may not be identified above. The Company funds other educational activities (including fellowships and non-physician and patient education); which are not included in this report.

<sup>2</sup> "Funding Amount" is the amount that the Company funded during Q4 2020 identified above based upon an agreement. Recipients are required to return any unused funds. Information on unused funds returned by the applicant on activities are not reported. "Funding Amount" does not include funds that may have been provided by other affiliated Sanofi Company Entities, (e.g., Sanofi Pasteur)

<sup>3</sup> Collaboration (Shared) Funding – is the full amount of a grant funded under an agreement with Regeneron, some or all of which may be shared between the collaborating entities.

## Independent Medical Education Grants

1<sup>st</sup> Oct 2020 – 31<sup>st</sup> Dec 2020

Sanofi US and its affiliate Genzyme Corporation are committed to supporting independent medical education activities in therapeutic areas in which the Company is involved, for healthcare professionals, patients, and consumers to improve patient care and health outcomes in therapeutic areas in which the Company is engaged. Sanofi US and Genzyme Corporation are part of the Sanofi Group, a global pharmaceutical company.

Recipient Name(s) <sup>1</sup>	Activity Title	Funding Amount <sup>2</sup>
The Board of Regents of the University of Nebraska	2021 Addressing Racial Disparities in Cancer Care and Incorporating Precision Medicine for Minority Populations Webinar Series	\$23,423
Physicians' Education Resource, LLC (PER)	ONS 2021: Cases and Conversations™ in Multiple Myeloma: Nursing Considerations for Managing Relapsed/Refractory Disease	\$96,465
Heath Science Educational Institute	Optimizing Management of Patients with Prostate Cancer- Increasing Screening, Diagnosis and Appropriate Treatment Selection	\$8,000
Oakstone Publishing Answers in CME Inc.	Bridging the Racial Gap in Multiple Myeloma Care: Increasing Awareness to Improve Treatment Outcomes	\$43,000
WebMD Health Corp Medscape, LLC	Best Practices for Preserving Joint Health in Hemophilia	\$88,230
Clinical Care Options, LLC	Integrating New Therapies into the Management of Relapsed/Refractory Myeloma: Experts Address the Paradox of Choice	\$75,000
i3 Health	The Oncology Nursing Showdown! Advanced Prostate Cancer Edition	\$60,000
ecancer	A Virtual Expert Panel Discussion to Improve Awareness and Understanding of the use of Targeted Therapies in the Treatment of Relapsed or Refractory Multiple Myeloma	\$21,470
Ebix, Inc touchIME	From Diagnosis to Treatment: Understanding the Role of Complement in Cold Agglutinin Disease	\$163,800
Physicians' Education Resource, LLC (PER)	"D" is for Diagnosis – Cracking the Case in Rare Hematologic Disorders: Practical Approaches to Accurate Identification and Management	\$178,875

<sup>1</sup> Applicant names are provided by the requestor. If applicants apply as a group for a single educational activity; all applicants may or may not be identified above. The Company funds other educational activities (including fellowships and non-physician and patient education); which are not included in this report.

<sup>2</sup> "Funding Amount" is the amount that the Company funded during Q4 2020 identified above based upon an agreement. Recipients are required to return any unused funds. Information on unused funds returned by the applicant on activities are not reported. "Funding Amount" does not include funds that may have been provided by other affiliated Sanofi Company Entities, (e.g., Sanofi Pasteur)

<sup>3</sup> Collaboration (Shared) Funding – is the full amount of a grant funded under an agreement with Regeneron, some or all of which may be shared between the collaborating entities.